Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2438]

ASCO 2014: Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

ASCO 2014: Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone...

20 years of the European Institute of Oncology

20 years of the European Institute of Oncology

Parasite causes cancer and infertility

Parasite causes cancer and infertility

Sexually transmitted protozoan parasite implicated in prostate cancer

Sexually transmitted protozoan parasite implicated in prostate cancer

Pancreatic cancer projected to become second leading cause of cancer-related death in the United States by 2030

Pancreatic cancer projected to become second leading cause of cancer-related death in the United States by 2030

Research in several cancers reveals promising treatment strategies, new insights on screening, and obesity-cancer link

Research in several cancers reveals promising treatment strategies, new insights on screening, and obesity-cancer...

Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing

Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing

NICE rejects use of abiraterone for advanced prostate cancer before chemo

NICE rejects use of abiraterone for advanced prostate cancer before chemo

Asprin could combat permanent hearing loss caused by cancer drug

Asprin could combat permanent hearing loss caused by cancer drug

Low testosterone levels may indicate worsening of disease for men with low-risk prostate cancer

Low testosterone levels may indicate worsening of disease for men with low-risk prostate cancer

More from ecancer